Furthermore, regardless of gender, age, BMI, primary tumor site, recurrence, composite score, skin response, or paronychia, only the first-line treatment being an anti-EGFR inhibitor administered for mCRC had a significant influence on OS and PFS. The gene discussed is EGFR; the disease is paronychia.